Booz Allen Hamilton: Analysts Lift Targets as Stock Surges Before Q2 Print

Booz Allen Hamilton reports second-quarter fiscal 2027 results on October 30 with a notable wave of analyst target upgrades arriving on the same day as the stock's sharpest weekly gain in months.

The analyst moves on Monday told a clear story. TD Cowen upgraded the stock to Buy from Hold, lifting its target to $95 from $77. Citi maintained its Neutral rating but raised its target to $88 from $77. BNP Paribas also held Neutral while lifting its target to $85 from $70. All three actions landed on October 26, the day the stock gained 6.4% to close at $83.36. That one-day move extended a weekly gain of 12.6%, well above the median 6.7% rise for its closest government-services peers including SAIC and Leidos. The consensus now stands at hold from 12 analysts, with 5 buys and 7 holds, and a mean price target of $88.31.

The debate centres on whether the worst of BAH's federal business headwinds is already in the price. The bull case rests on a roughly 10% free cash flow yield, a current EV/EBITDA near 10x, and the company's own FY2027 initial guidance that flagged 0% to 4% revenue growth alongside improving margins and $825 million to $925 million of free cash flow. The FY4Q26 quarter that the company just filed showed adjusted EBITDA margins improving to 11.1% and backlog growing 3.1% year over year to $38 billion, even as revenues fell 6.4%. Bears focus on the ongoing drag from Civil-facing contracts, the risk that cost-plus programs face further pricing pressure under current administrative priorities, and the concern that the stock, having re-rated from deeply depressed levels, now trades without much buffer if near-term execution disappoints.

Short positioning gives little indication of conviction on either side. Short interest is 5.6% of the free float, and it has fallen roughly 7.4% over the past month as the stock recovered. Borrowing shares is almost trivially cheap at 0.41% annualised, and availability in the lending market is exceptionally loose, with shares available to borrow running at more than 52 times the current short interest. The ORTEX short score of 41, in the 31st percentile, confirms there is no meaningful short-side pressure building into the print.

The October 30 release is therefore less a test of whether the company can grow and more a question of whether the margin and backlog trajectory seen in the last quarter has continued, and whether management's initial guidance range holds at a moment when the Street has just moved its targets sharply higher.